Fig. 1.
Effects of 6D1 and PP1 on platelet agglutination/aggregation.
Human washed platelets (2 × 108/mL) (panel A) and Bernard-Soulier syndrome washed platelets (1.5 × 108/mL) (panel B) were preincubated for 5 minutes with vehicle (dimethyl sulfoxide 0.1%); anti-GPIbα mAb 6D1 (10 μg/mL); the Src family kinase inhibitor PP1 (10 μM); or mAb 6D1 and PP1 in combination. This was followed by stimulation with convulxin (Cvx; 1 μg/mL); alboaggregin-A (Alb-A; 1 μg/mL); and vWF ristocetin (vWF-rist; 10 μg/mL and 1 mg/mL, respectively). Experiments were conducted in aggregometer cuvettes with stirring at 37°C. Results are representative of 3 to 8 experiments.
